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Abstract
Background: Necrotizing pneumonia attributed to Panton-Valentine leukocidin-positive Staphylococcus aureus has
mainly been reported in otherwise healthy children and young adults, with a high mortality rate. Erythroderma,
airway bleeding, and leukopenia have been shown to be predictive of mortality. The objectives of this study were
to define the characteristics of patients with severe leukopenia at 48-h hospitalization and to update our data
regarding mortality predicting factors in a larger population than we had previously described.
Methods: It was designed as a case-case study nested in a cohort study. A total of 148 cases of community-
acquired, necrotizing pneumonia were included. The following data were collected: basic demographic information,
medical history, signs and symptoms, radiological findings and laboratory results during the first 48 h of
hospitalization. The study population was divided into 2 groups: (1) with severe leukopenia (leukocyte count ≤3,000
leukocytes/mL, n=62) and (2) without severe leukopenia (>3,000 leukocytes/mL, n=86).
Results: Median age was 22 years, and the male-to-female gender ratio was 1.5. The overall in-hospital mortality
rate was 41.2%. Death occurred in 75.8% of severe leukopenia cases with median survival time of 4 days, and in
16.3% of cases with leukocyte count >3,000/mL (P<0.001). Multivariate analysis indicated that the factors associated
with severe leukopenia were influenza-like illness (adjusted odds ratio (aOR) 4.45, 95% CI (95% confidence interval)
1.67-11.88, P=0.003), airway bleeding (aOR 4.53, 95% CI 1.85-11.13, P=0.001) and age over 30 years (aOR 2.69, 95% CI
1.08-6.68, P=0.033). A personal history of furuncles appeared to be protective (OR 0.11, 95% CI 0.01-0.96, P=0.046).
Conclusion: S. aureus-necrotizing pneumonia is still an extremely severe disease in patients with severe leukopenia.
Some factors could distinguish these patients, allowing better initial identification to initiate adapted, rapid
administration of appropriate therapy.
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Background
Since the description of necrotizing pneumonia due to
Panton-Valentine leukocidin (PVL)-positive Staphylococ-
cus aureus by Gillet et al. in 2002, numerous cases have
been reported worldwide [1-7]. They mainly impacted
otherwise healthy children and young adults, with a
median age of 14 years. They are attributed to either
methicillin-sensitive or -resistant S. aureus strains of
various genetic backgrounds, but have all PVL genes in
common [8,9]. Necrotizing pneumonia is characterized
by rapid, extensive, bilateral pneumonia frequently
evolving towards acute respiratory distress syndrome
(ARDS), despite intensive medical interventions with
mechanical ventilation and inotrope support. No specific
treatment guidelines have been published so far, but
the addition of toxin-suppressing antibiotics, such as
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The overall mortality rate ranges from 30 to 75% of
cases [3,13]. The fatal outcome is rapid, with median
survival time between 4 to 10 days from the onset of
symptoms [1,4,12]. It is associated with classic severity
factors, such as the need for mechanical ventilation or
inotrope support, and the onset of ARDS. Erythroderma,
airway bleeding, and leukopenia have been shown to be
predictive of mortality. Gillet et al. reported significant
differences, by multivariate analysis, in median leukocyte
count between patients who survived and those who did
not. The survival rate was <10% when the leukocyte
count was <3,000 leukocytes/mL. The leukopenia ob-
served in patients could reflect PVL cytotoxicity, demon-
strated in vitro on human neutrophils [14,15].
As patients with leukopenia face a high risk of mortal-
ity, better initial recognition of these severe cases would
allow rapid administration of appropriate treatment. In
this study, a series of 148 cases of S. aureus-necrotizing
pneumonia was analyzed. Our aim was to define the
characteristics of patients with severe leukopenia at 48-h
hospitalization and to update our data regarding mortal-




Since 1986, the French National Reference Centre of
Staphylococci (Lyon, France) has collected 161 case re-
ports of documented pneumonia caused by S. aureus
strains carrying PVL genes (lukS-PV—lukF-PV). In-
formed consent was waived because data were extracted
from the surveillance database. According to French law,
a study like this one does not require ethics committee
approval because it is observational and based on a sur-
veillance database approved under national regulations.
The protocol design was approved by the hospital’s insti-
tutional review board (Comité National Informatique et
Liberté).
Definitions
Pneumonia was defined by signs and symptoms of lower
respiratory tract infection (e.g., cough, expectoration,
and chest pain) and pulmonary infiltrates on chest X
Ray reviewed by a radiologist, that were not attributable
to other causes, but coinciding with S. aureus isolation
by at least 1 of the following procedures: (1) pleural effu-
sion or lung abscess; (2) broncho-alveolar lavage fluid
culture (104 CFU/mL), Wimberley brushing (103 CFU/
mL), or protected tracheal aspiration (103 CFU/mL); and
(3) blood culture revealing S. aureus as the sole potential
pathogen. Cases with respiratory symptoms starting at
least 48 h after hospitalization were classified as nosoco-
mial and were excluded from the study. Leukopenia was
defined as severe if median leukocyte count was < 3,000
leukocytes/mL within the first 48 h after hospital
admission.
Microbiological studies
S. aureus isolates were tested for antimicrobial susceptibil-
ity and toxin production. Testing of isolates for antimicro-
bial susceptibility by broth microdilution was undertaken
according to the interpretive criteria of the Clinical and
Laboratory Standards Institute (formerly the National
Committee for Clinical Laboratory Standards). The fol-
lowing antimicrobial agents were used: penicillin, oxacil-
lin, kanamycin, tobramycin, gentamicin, erythromycin,
clindamycin, tetracycline, ofloxacin, fusidic acid, rifampi-
cin, vancomycin, teicoplanin, fosfomycin, trimethoprim-
sulfamethoxazole, and linezolid. Gene sequences encoding
superantigens (enterotoxins A-E, G-I, and toxic shock
syndrome toxin), PVL and mecA gene, which codes for
methicillin resistance, were detected by PCR, as described
elsewhere [16]. Only cases caused by PVL-positive S. aur-
eus strains were included.
Study design and population
Designed as a case-case study nested in a cohort study,
analyses were restricted to 148 cases where all clinical
and biological data were available.
Data collection
The following data were collected by a standardized
form and comprised basic demographic information,
medical history (including risk factors for infection and
history of personal or familial abscesses or furuncles),
signs and symptoms, radiological findings and laboratory
results during the first 48 h of hospitalization. Severity
was rated by Pediatric Risk of Mortality (PRISM) 3
scores for patients <18 years and the Simplified Acute
Physiology Score (SAPS) II for patients ≥18 years, when
available. Some biological and radiological data were
missing because of death shortly after admission to
hospital.
Statistical analysis
Categorical variables were compared by the Chi-square
or Fisher’s exact test, and continuous variables, by Stu-
dent’s t-test or Mann–Whitney tests. Survival probability
according to median leukocyte count, was estimated by
the Kaplan-Meier method. Initially the cases were di-
vided into 3 groups: 0–3,000; 3,000-10,000 and >10,000
leukocytes/mL but we merged the data of the last two
groups since no significant difference was found for vari-
ables included in the final multivariate regression model
(data not shown in this paper). The ROC analysis
showed a 84% sensitivity for a cut-off of 3000 leuko-
cytes/mL.
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Baseline was the day of admission to hospital because
of pneumonia, and patients who survived were censored
at hospital discharge. When patients died within 24 h
after admission, the observation period was rounded to
1 day. Survival distributions were compared by the log-
rank test. Variables independently associated with sur-
vival were identified with a Cox regression model based
on hazard ratios with 95% confidence interval (95% CI).
Variables associated with severe leukopenia were
tested by the multivariate logistic regression model.
When P values of variables described in the first table,
were <0.20 in univariate analysis, they were submitted to
the multivariate model. Variables in multivariate analysis
were subjected to the forced entry procedure, with step-
wise and backward elimination, using P values of 0.1 as
criteria for inclusion and elimination of risk variables
based on best subset logistic regression with Chi-square
score fit criteria. The Hosmer-Lemeshow test assessed
the model’s goodness-of-fit. Adjusted odds ratios (aOR)
and corresponding 95% CI were calculated. For all tests
performed, 2-tailed P values < 0.05 were regarded as de-
noting statistical significance. Analyses were performed
with SPSS 17.0 software (SPSS Inc., Chicago, IL, USA).
Results
From 1986 through 2010, 161 cases of community-
acquired, necrotizing pneumonia were collected and
documented; 13 case reports were excluded because of
missing data concerning leukocytes count.
Demographic conditions and medical history
In total, 148 cases of community-acquired necrotizing
pneumonia were included. Median age was 22 years
(interquartile range [IQR] 3.0-43.7) and the male-to-fe-
male gender ratio was 1.5 (88 males and 60 females).
Smoking was reported in 15.5% patients. Common risk
factors for staphylococcal infection, such as diabetes,
steroid therapy, and immunosuppressive treatment, were
noted for 6.1%, 6.8% and 5.4% of patients, respectively.
Among the 126 patients for whom data were available,
10.3% had a personal history of furuncles or skin
abscess.
The median duration of symptoms prior to hospitalization
was 3.0 days (IQR 2.0-5.0 days), with preceding influenza-
like syndrome in 61.7% (87 of 141), and pre-existing skin
and soft tissue infection (SSTI) in 22.3% (33 of 143).
Clinical and biological data
The clinical course during the first 48 h after hospital
admission was usually severe, with 63.5% of patients re-
quiring mechanical ventilation. The most remarkable
clinical feature was airway bleeding, which occurred in
40.0% of patients. S. aureus was recovered from blood
culture in 60.8%, in pleural fluid from 40.5%, and in tra-
cheal aspirates from 12.8% of patients.
Median minimal leukocyte count during the first 48 h
of hospitalization was 4,700 leukocytes/mL (IQR 1,300-
12,800 leukocytes/mL), and 41.9% had leukocyte count
≤3,000 leukocytes/mL. The minimal platelet count was
also low, with a median of 168,000 platelets/mL (IQR
88,000-275,000 platelets/mL).
The overall in-hospital mortality rate was 41.2%. 98.4%
of deaths were attributed to S. aureus and were second-
ary to refractory shock and/or respiratory failure.
Factors associated with severe leukopenia
The study population was divided into 2 groups: (1) with
severe leukopenia (leukocyte count ≤3,000 leukocytes/
mL, n=62) and (2) without severe leukopenia (>3,000
leukocytes/mL, n=86).
The group with severe leukopenia was characterized
by a significantly higher rate of female patients
(P=0.008) (Table 1). Prior influenza-like illness (ILI:
79.3% vs. 49.4%, P<0.001) and airway bleeding (62.9% vs.
23.3% (P<0.001) were also associated with severe
leukopenia. Conversely, a personal history of furuncles
or skin abscess (P=0.001) and SSTI at admission
(P=0.002) were more frequent in the group without se-
vere leukopenia. The group with severe leukopenia
presented ARDS onset more frequently and needed arti-
ficial ventilation or inotrope support (P<0.001).
Multivariate analysis indicated that ILI, airway bleed-
ing and age over 30 years were independent factors asso-
ciated with severe leukopenia (Table 2). A personal
history of furuncles appeared to be protective.
Survival analysis
Leukocyte count was negatively correlated with mortal-
ity. Death occurred in 75.8% of cases (47 of 62) with se-
vere leukopenia (≤3,000 leukocytes/mL) with median
survival time of 4 days (Figure 1). Only 16.3% of cases
(14 of 86) with leukocyte count >3,000/mL (P<0.001)
died. Mortality was 66% in cases with airway bleeding
versus 24.7% in those without (P<.001). Cox multivariate
analysis indicated that the only factors associated with
fatal outcome were leukopenia, airway hemorrhage and
age (Table 3).
Discussion
In this article, we compared the characteristics of
a group of 62 cases of severe leukopenia (≤3,000
leukocytes/mL) with a group of 86 patients without
severe leukopenia (>3,000 leukocytes/mL) at 48 h of
hospitalization.
The group with severe leukopenia was exemplified by
a significantly higher rate of female patients (P=0.008),
prior ILI (P<0.001) and airway bleeding (P<0.001).
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Conversely, a personal history of furuncles or skin ab-
scess (P=0.001) and SSTI at admission (P=0.002) were
more frequent in the group without severe leukopenia.
The mortality rate was significantly different between
groups (75.8% vs 16.3%, P<0.001).
Necrotizing pneumonia largely occurred in young
people with a median age of 22 years, only slightly
higher than reported earlier in smaller series
[1,3,7,13,17]. The increasing of age of included pa-
tients might be attibuable to a delayed exposure to
Table 1 Characteristics of severe and non-severe leukopenia in a French cohort of 148 patients with S. aureus-
necrotizing pneumonia, between 1986 and 2010







0-30 32 (51.6) 55 (64.0) 0.132
>30 30 (48.4) 31 (36.0)
Gender, M:F (ratio) 29:33 (46.8) 59:27 (68.6) 0.008
Medical history
Smoking 7 (12.5) 16 (19.5) 0.278
Alcohol 1 (1.7) 3 (3.7) 0.479
Steroid treatment 2 (3.3) 7 (8.3) 0.222
Respiratory failure 0 (0) 3 (3.5) 0.138
Personal history of furuncles or skin abscess 1 (2.0) 12 (16.0) 0.011
Before hospital admission
Period between onset of symptoms and admissiona 3 (2-4) 3 (2-5) 0.684
Influenza-like illness 46 (79.3) 41(49.4) <0.001
SSTIb 6 (9.7) 27 (31.4) 0.002
Clinical features within the first 48 h of hospitalization
PRISM scorea, b 27 (20-35) 6 (4-11) <0.001
SAPS II scorea, b 67 (39-80) 28 (15-61.8) <0.001
Platelet count/mL 92,000 (46,500-176,500) 204,000 (145,000-370,000) <0.001
Fever, temperature >39°C 46 (64.2) 70 (81.4) 0.294
Generalized rash 24 h 5 (8.3) 6(7.0) 0.760
Airway hemorrhage 39 (62.9) 20 (23.3) <0.001
Pleural effusion 16 (27.1) 49 (57.6) <0.001
Radiological consolidation 0.001
Unilobar 6 (9.8) 30 (34.9)
Multilobar 48 (78.7) 44 (51.2)
ARDSb 47 (77.0) 15 (18.1) <0.001
Methicillin resistance (mecAgene) 15 (24.2) 20 (23.3) 0.895
Treatment and outcome
Mechanical ventilation 57 (91.9) 37 (43.0) <0.001
Inotrope drugs 52 (91.2) 21 (26.3) <0.001
Time to deatha 2 (1-6) 2 (1-2.75) 0.216
Appropriate antibiotics introduced in first 24 h of h
hospitalization
46 (75.4) 65 (75.6) 0.161
Mortality 47 (75.8) 14 (16.3) <0.001
Percentage of deaths attributed to S. aureus infection 47 (100) 13 (92.9) 0.065
aContinuous variables are indicated as median, first and third quartiles and categorical variables as number (%).
bSSTI: skin and soft tissue infection, PRISM: Pediatric Risk of Mortality; SAPS II: Simplified Acute Physiology Score; ARDS: acute respiratory distress syndrome.
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the causative organism. This epidemiological trend
should be challenged by similar surveys in other
countries. This effect could be related to the im-
provement of the management of this infection.
Our study confirms the association of leukocyte count
with disease severity. By multivariate logistic regression,
age over 30 years was associated with severe leukopenia
(aOR 2.69, P=0.033). The reason of this association was
not clear. The increasing of age of patients might be
attibuable to a delayed exposure to the causative organ-
ism. This epidemiological trend should be challenged by
similar surveys in other countries. An association be-
tween time and lymphocyte count was actually reported
in different populations [18,19].
Female gender was associated with severe leukopenia
(OR 2.49, P=0.008) by univariate analysis but not by
multivariate analysis. Females in general mount a more
profound immune response after antigenic challenge,
and these differences have mainly been attributed to the
immunomodulatory effects of sex hormones, despite the
Table 2 Factors associated with severe leukopenia among
patients with Panton-Valentine leukocidin-positive
Staphylococcus aureus-associated necrotizing pneumonia
Variablesa Adjusted odds ratios (95% CI) P value
Previous influenza-like illness 4.45 (1.67-11.88) 0.003
Age >30 years 2.69 (1.08-6.68) 0.033
Airway hemorrhage 4.53 (1.85-11.13) 0.001
Personal history of furuncles 0.11 (0.01-0.96) 0.046
aVariables were adjusted to gender, mechanical ventilation, platelet count,
pleural effusion, and time elapsed between onset of symptoms
and hospitalization.
Figure 1 Probability of survival among patients with Panton-Valentine leukocidin-positive Staphylococcus aureus pneumonia,
according to leukocyte count.
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lack of human in vivo data. Even though we still found
some papers reporting an association of neutropenia
with female gender. vanEijk et al. demonstrated, in an
in vivo study, that females exert a more pro-
inflammatory pattern of cytokine release compared to
males during systemic inflammation after the adminis-
tration of Escherichia coli endotoxin [20]. This difference
is associated with more leukocyte sequestration in fe-
males [20]. Sterling et al. reported gender-based differ-
ences in host immune responses [21]. In a study
analyzing the risk factors for developing neutropenia
after mitomycin C administration, multivariate logistic
regression showed that female gender was an independ-
ent risk factor for neutropenia and the reasons for this
association are unknown [22].
The significant association with a previous ILI (aOR
4.45, P=0.003) might be related to a particular linkage
with influenza virus. Possible epithelial damage, due to
viral infection, could promote the pathogenicity of PVL-
producing strains with increasing affinity for collagen
(I and IV) and laminin [23].
A personal history of furuncles appears to be protect-
ive (OR 0.11, 95% CI 0.01-0.96, P=0.046). It is conceiv-
able that patients with such a history had previously
been exposed to PVL and had developed a degree of
protective immunity [24]. Another hypothesis could ex-
plain this association: after bacteria reach the lungs
through the bloodstream, the necrotizing effect is less
serious.
The present investigation has some limitations. First,
case reporting to the Reference Center was unsolicited
and may not reflect accurate epidemiology and disease
severity. Severe and dramatic cases among previously-
healthy young people are more likely to be reported. A
bias of notification would not be excluded. This would
be caused by some missing data possibly not declared
after 2000 due to the dispersion of laboratories dealing
with PVL gene detection.
Moreover the median age was slightly higher than had
been previously reported which could be related to the
introduction of several novelties in the treatment of
severely ill patients since the identification of this
pathology.
Another limitation concerns clinical data collection:
they were missing or incomplete in 8% of cases. Ana-
lysis included only 148 cases for which microbio-
logical and demographic information were available;
13 cases were excluded from further analysis because
they lacked data on leukocyte count. Comparisons be-
tween the 13 excluded cases and the 148 cases ana-
lyzed revealed no significant differences.
Leukopenia may be simply considered as a reflec-
tion of disease severity. This is in agreement with
in vitro data showing that PVL induces both apop-
tosis and necrosis in human leukocytes [25]. The time
period between the onset of symptoms and hospitalization
could be important to reach a certain level of severity
and impaired leukocyte count, but it was not different
between both groups. On the other hand, multivariate
logistic regression was adjusted to the time factor.
Furthermore we noticed that factors associated with
severe leukopenia were quite different from those as-
sociated with mortality.
Based on our results, we can suggest two syn-
dromes of necrotizing pneumonia: 1) those that are
mainly related to ILI and direct inoculation of
staphylococci to damaged respiratory epithelium, air-
way hemorrhage, severe leukopenia and death; and
2) those that are mainly related to hematogenous
spread from SSTI, less airway hemorrhage, without
leukopenia and improved survival. In conclusion, our
study emphasizes that S. aureus-necrotizing pneumo-
nia is still an extremely severe disease. We found that
some factors could distinguish patients with severe
leukopenia from those without leukopenia.
Leukocytes count is promptly available at admission to
the hospital and can be easily used to asses the severity
of disease as suggested by this paper. The impact of this
marker, on patient management, need to be clarified.
Empiric therapy should include coverage for S. aureus as
soon as possible, without waiting for the bacteriological
results.
Clinical data indicate that neutralizing toxin produc-
tion improves the outcome [26,27]. The toxin can be
blocked by combining a toxin-suppressing agent (e.g.,
clindamycin, linezolid or rifampin) with bactericidal an-
tibiotics acting on the cell wall [10].
Conclusions
S. aureus-necrotizing pneumonia is still an extremely se-
vere disease in patients with severe leukopenia. Some
factors like leukocytes count could distinguish these pa-
tients, allowing better initial identification to initiate
adapted, rapid administration of appropriate therapy.
This paper could be regarded as a preliminary work.
Table 3 Factors associated with death among patients





Age (per 1-year increase) 1.02 (1.01-1.03) 0.015




Variables were adjusted to gender, mechanical ventilation, personal history of
furuncles, platelet count, pleural effusion, and previous influenza-like illness.
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Experts are invited to work on a widely accepted score,
validate a score including leukocytes count, to predict
the severity of this disease.
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